PLIANT THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
PLIANT THERAPEUTICS, INC. (PLRX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2021-05-10
- PLIANT THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2021-03-31 was $0.00.
- PLIANT THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2020-12-31 was $0.00.
- PLIANT THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2020-09-30 was $0.00.
- PLIANT THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2020-06-30 was $0.00.
- PLIANT THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2020 was $0.00.
- PLIANT THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2019 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 | $0.00 derived: sum of 2 quarters · filed 2021-05-10 | $0.00 derived: sum of 3 quarters · filed 2021-05-10 | $0.00 derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $0.00 derived: sum of 3 quarters · filed 2021-03-16 | $0.00 10-K · filed 2021-03-16 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | $0.00 derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $0.00 10-Q · filed 2020-08-11 | $0.00 derived: sum of 3 quarters · filed 2021-05-10 | $0.00 derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 | $0.00 derived: sum of 2 quarters · filed 2021-05-10 | $0.00 derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $0.00 10-K · filed 2021-03-16 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |